FrancophonIA/ELRC3.0 huggingface dataset:
English: RA studies III and V had an additional primary endpoint at 52 weeks of retardation of disease progression (as detected by x-ray results).
Croatian: Dodatni primarni ishod ispitivanja RA III i V bilo je usporavanje progresije bolesti (na temelju radioloških nalaza) nakon 52 tjedna liječenja.
English: Put the original package with any unused syringes back in the refrigerator.
Croatian: Vratite u hladnjak originalnu kutiju s neiskorištenim štrcaljkama.
English: a p-value is from the pairwise comparison of methotrexate monotherapy and adalimumab/methotrexate combination therapy using the Mann-Whitney U test b p-value is from the pairwise comparison of adalimumab monotherapy and adalimumab/methotrexate combination therapy using the Mann-Whitney U test c p-value is from the pairwise comparison of adalimumab monotherapy and methotrexate monotherapy using the Mann-Whitney U test
Croatian: rezultat a p-vrijednost dobivena sparenom usporedbom monoterapije metotreksatom i kombinirane terapije adalimumabom i metotreksatom uz primjenu Mann-Whitney U testa b p-vrijednost dobivena sparenom usporedbom monoterapije adalimumabom i kombinirane terapije adalimumabom i metotreksatom uz primjenu Mann-Whitney U testa c p-vrijednost dobivena sparenom usporedbom monoterapije adalimumabom i monoterapije metotreksatom uz primjenu Mann-Whitney U testa
English: ● Put the used pre-filled pen in a sharps disposal container immediately after use.
Croatian: Odložite iskorištenu napunjenu brizgalicu u spremnik za odlaganje oštrih predmeta odmah nakon korištenja.
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
Croatian: 11. NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET
English: In controlled and open-label adult and paediatric studies with adalimumab, serious infections (including fatal infections, which occurred rarely) have been reported, which include reports of tuberculosis (including miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated or extrapulmonary histoplasmosis, blastomycosis, coccidioidomycosis, pneumocystis, candidiasis, aspergillosis and listeriosis).
Croatian: U kontroliranim i otvorenim ispitivanjima adalimumaba u odraslih i djece zabilježene su ozbiljne infekcije (u rijetkim slučajevima i sa smrtnim ishodom), među kojima i tuberkuloza (uključujući njezin milijarni oblik i izvanplućne lokalizacije) te invazivne oportunističke infekcije (npr. diseminirana ili ekstrapulmonalna histoplazmoza, blastomikoza, kokcidioidomikoza, pneumocistis, kandidijaza, aspergiloza i listerioza).
English: Adalimumab 80/40 mg N = 75
Croatian: 80/40 mg N = 75
English: For patients who dose escalated from every other week to weekly regimen, the mean (±SD) serum concentrations of adalimumab at week 52 were 15.3 ± 11.4 μg/mL (40/20 mg, weekly) and 6.7 ± 3.5 μg/mL (20/10 mg, weekly).
Croatian: U bolesnika čija je učestalost doziranja povišena sa svaka dva tjedna na svaki tjedan, srednje vrijednosti (±SD) koncentracija adalimumaba u serumu u 52. tjednu bile su 15,3 ± 11,4 μg/ml (40/20 mg, tjedno) i 6,7 ± 3,5 μg/ml (20/10 mg, tjedno).
English: ACR response in placebo-controlled psoriatic arthritis studies (percent of patients)
Croatian: ACR odgovor u placebom kontroliranim ispitivanjima kod psorijatičnog artritisa (postotak bolesnika)
English: Each pack contains 1, 2, 4 or 6 single-use 40 mg pre-filled syringes (with blue plunger rod).
Croatian: Jedno pakiranje sadrži 1, 2, 4 ili 6 napunjenih štrcaljki od 40 mg za jednokratnu primjenu (s plavim klipom).
English: Placebo Adalimumab 40 mg weekly
Croatian: Placebo Adalimumab 40 mg svaki tjedan
English: For patients who stayed on their randomised therapy, the mean (±SD) adalimumab trough concentrations at week 52 were 9.5 ± 5.6 μg/mL for the standard dose group and 3.5 ± 2.2 μg/mL for the low dose group.
Croatian: U bolesnika koji su nastavili terapiju na koju su randomizirani, srednje vrijednosti (±SD) najnižih koncentracija adalimumaba u 52. tjednu bile su 9,5 ± 5,6 µg/ml za skupinu koja je primala standardnu dozu i 3,5 ± 2,2 µg/ml za skupinu koja je primala nisku dozu.
English: Adalimumab/methotrexate patients demonstrated significantly less radiographic progression than patients receiving methotrexate alone at 6 and 12 months (see table 9).
Croatian: Radiološki nalazi u bolesnika liječenih kombinacijom adalimumaba i metotreksata pokazali su znatno sporiju progresiju strukturnih oštećenja zglobova nego u bolesnika liječenih samo metotreksatom tijekom 6 i 12 mjeseci (vidjeti Tablicu 9).
English: AMGEVITA is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.
Croatian: AMGEVITA je indicirana za liječenje aktivnog i progresivnog psorijatičnog artritisa u odraslih bolesnika u kojih prethodnim liječenjem antireumaticima koji modificiraju tijek bolesti nije postignut zadovoljavajući odgovor.
English: Important: Always hold the pre-filled syringe by the syringe barrel.
Croatian: Važno: Uvijek držite napunjenu štrcaljku za spremnik štrcaljke.
English: Antibiotics may be continued during treatment with AMGEVITA if necessary.
Croatian: Ako je potrebno, primjena antibiotika može se nastaviti i tijekom liječenja lijekom AMGEVITA.
English: Reduction of inflammatory lesions and prevention of worsening of abscesses and draining fistulas was assessed using Hidradenitis Suppurativa clinical response (HiSCR; at least a 50% reduction in total abscess and inflammatory nodule count with no increase in abscess count and no increase in draining fistula count relative to Baseline).
Croatian: Hidradenitis Suppurativa Clinical Response [HiSCR]; smanjenje ukupnog broja apscesa i upalnih nodula za najmanje 50%, bez povećanja broja apscesa i bez povećanja broja drenirajućih fistula u odnosu na početnu vrijednost).
English: RA study Ia**
Croatian: Ispitivanje RA Ia**
English: In adult Crohn's disease studies, higher incidences of malignant and serious infection-related adverse events were seen with the combination of adalimumab and azathioprine/6-mercaptopurine compared with adalimumab alone.
Croatian: U ispitivanjima kod Crohnove bolesti u odraslih, kod kombinacije adalimumaba i azatioprina/6merkaptopurina primijećene su veće incidencije nuspojava povezanih sa zloćudnim bolestima i ozbiljnim infekcijama nego kod primjene samo adalimumaba.
English: Week 12 results showed statistically significant improvement of the signs and symptoms of active nr-axSpA in patients treated with adalimumab compared to placebo (table 14).
Croatian: Rezultati u 12. tjednu pokazali su statistički značajno poboljšanje znakova i simptoma aktivnog nr-axSpA u bolesnika koji su liječeni adalimumabom u odnosu na placebo (Tablica
English: AMGEVITA Dose for Paediatric Patients with Crohn's disease
Croatian: Tablica 4. Doza lijeka AMGEVITA za pedijatrijske bolesnike s Crohnovom bolešću
English: Detailed information is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Croatian: Detaljne informacije su dostupne na internetskoj stranici Europske medicinske agencije http//:www.ema.europa.eu.
English: In RA study III, where adalimumab-treated patients had a mean duration of rheumatoid arthritis of approximately 11 years, structural joint damage was assessed radiographically and expressed as change in modified Total Sharp Score (TSS) and its components, the erosion score and joint space narrowing score.
Croatian: U ispitivanju RA III, u kojem je srednje trajanje reumatoidnog artritisa u bolesnika liječenih adalimumabom bilo 11 godina, strukturno oštećenje zglobova procjenjivalo se radiološki, a izraženo je promjenom ukupnog zbroja bodova prema modificiranoj Sharpovoj ljestvici (engl.
English: ACR 20 Week 12 Week 24
Croatian: ACR 20 12. tjedan 24. tjedan
English: AMGEVITA is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.
Croatian: AMGEVITA je indicirana za liječenje neinfektivnog intermedijarnog, posteriornog i panuveitisa u odraslih bolesnika u kojih nije postignut zadovoljavajući odgovor na kortikosteroide, kojima je potrebna poštedna primjena kortikosteroida ili u kojih liječenje kortikosteroidima nije prikladno.
English: If symptoms of tuberculosis (persistent cough, weight loss, listlessness, mild fever), or any other infection appear during or after therapy, tell your doctor immediately.
Croatian: Jave li se za trajanja ili nakon liječenja simptomi tuberkuloze (uporan kašalj, gubitak tjelesne težine, bezvoljnost, blaga vrućica) ili neke druge infekcije, javite odmah svom liječniku.
English: After single intravenous doses ranging from 0.25 to 10 mg/kg,
Croatian: Nakon pojedinačnih intravenskih doza koje su se kretale od 0,25 do 10 mg/kg, koncentracije su bile proporcionalne dozi.
English: If adequate response is achieved with 40 mg every week or 80 mg every other week, the dosage may subsequently be reduced to 40 mg every other week.
Croatian: Ako se s povećanjem doziranja 40 mg svaki tjedan ili 80 mg svaki drugi tjedan postigne zadovoljavajući odgovor, doziranje se potom može smanjiti na 40 mg svaka dva tjedna.
English: Paediatric CD study discontinuation of corticosteroids or immunomodulators and fistula remission
Croatian: Tablica 27. Ispitivanje kod Crohnove bolesti u djece prestanak uzimanja kortikosteroida ili imunomodulatora i remisija fistula
English: AMGEVITA in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs).
Croatian: AMGEVITA je, u kombinaciji s metotreksatom, indicirana za liječenje aktivnog poliartikularnog juvenilnog idiopatskog artritisa u bolesnika u dobi od 2 godine i starijih u kojih prethodnim liječenjem jednim ili više antireumatika koji modificiraju tijek bolesti (engl. disease-modifying anti-rheumatic drug, DMARD) nije postignut zadovoljavajući odgovor.
English: Figure 3: Kaplan-Meier curves summarising time to treatment failure in the paediatric uveitis study
Croatian: Slika 3: Kaplan-Meierove krivulje koje sažeto prikazuju vrijeme do neuspjeha liječenja u ispitivanju liječenja uveitisa u djece
English: Statistically significant increases (improvement) from baseline to week 26 and 52 in body mass index and height velocity were observed for both treatment groups.
Croatian: U obje skupine su zabilježena statistički značajna povećanja (poboljšanja) indeksa tjelesne mase i brzine rasta u 26. i 52. tjednu u odnosu na početne vrijednosti.
English: Patients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosis infection (e.g. persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after therapy with AMGEVITA.
Croatian: Bolesnike se mora upozoriti da se obrate liječniku ako se za vrijeme ili nakon liječenja lijekom AMGEVITA pojave znakovi/simptomi koji upućuju na tuberkuloznu infekciju (npr. perzistirajući kašalj, progresivno propadanje/gubljenje težine, blago povišena tjelesna temperatura, bezvoljnost).
English: F. Pinch your injection site to create a firm surface.
Croatian: Uhvatite područje injiciranja kako biste stvorili čvrstu površinu.
English: Clinical response is decrease from baseline in Mayo score ≥ 3 points and ≥ 30% plus a decrease in the rectal bleeding subscore [RBS] ≥ 1 or an absolute RBS of 0 or 1; * p < 0.05 for adalimumab versus placebo pairwise comparison of proportions ** p < 0.001 for adalimumab versus placebo pairwise comparison of proportions a Of those receiving corticosteroids at baseline
Croatian: Klinički odgovor je postignut ako je ostvareno smanjenje Mayo rezultata u odnosu na početne vrijednosti od ≥ 3 boda i ≥ 30%, uz smanjenje podrezultata rektalnog krvarenja [engl. rectal bleeding subscore, RBS] od ≥ 1 ili apsolutni RBS od 0 ili 1; * p < 0,05 za adalimumab naspram placeba, sparena usporedba udjela ** p < 0,001 za adalimumab naspram placeba, sparena usporedba udjela a onih koji su na početku uzimali kortikosteroide
English: The adjusted OR (accounting for baseline differences) was 1.10 (95% CI 0.45-2.73) with RA and CD
Croatian: Prilagođen OR (kod kojega su uzete u obzir početne razlike) iznosio je 1,10 (95% CI: 0,45 - 2,73) za reumatoidni artritis i Crohnovu bolest zajedno.
English: Partial Flared a Assessment of SpondyloArthritis international Society b Baseline is defined as open label baseline when patients have active disease.
Croatian: Assessment of Spondyloarthritis International Society) b Početna vrijednost definirana je kao početna vrijednost otvorenog ispitivanja kada bolesnici imaju aktivnu bolest c Rezultat za aktivnost ankilozantnog spondilitisa (engl.
English: Myocardial infarction1), Arrhythmia, Congestive heart failure
Croatian: često tahikardija manje često infarkt miokarda1), aritmija, kongestivno zatajenje srca rijetko zastoj srca
English: The mean (±SD) serum adalimumab trough concentrations achieved at week 4 were 15.7 ± 6.6 μg/mL for patients ≥ 40 kg (160/80 mg) and 10.6 ± 6.1 μg/mL for patients < 40 kg (80/40 mg).
Croatian: Srednje vrijednosti (±SD) najnižih koncentracija adalimumaba u serumu u 4. tjednu bile su 15,7 ± 6,6 µg/ml u bolesnika tjelesne težine ≥ 40 kg (160/80 mg) i 10,6 ± 6,1 µg/ml u bolesnika tjelesne težine < 40 kg (80/40 mg).
English: Pack size of one pre-filled syringe.
Croatian: Pakiranje od jedne napunjene štrcaljke.
English: Clinical remission Clinical response (CR-100) Patients in steroid-free remission for > = 90 daysa * p < 0.001 for adalimumab versus placebo pairwise comparisons of proportions ** p < 0.02 for adalimumab versus placebo pairwise comparisons of proportions a Of those receiving corticosteroids at baseline
Croatian: Klinička remisija Klinički odgovor (CR-100) Bolesnici u remisiji bez primjene steroida > = 90 danaa * p < 0,001 za adalimumab naspram placeba, sparena usporedba udjela **p < 0,02 za adalimumab naspram placeba, sparena usporedba udjela a Onih koji su na početku uzimali kortikosteroide
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION AMGEVITA 40 mg injection adalimumab
Croatian: NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA AMGEVITA 40 mg injekcija adalimumab s.c.
English: Adalimumab 160/80 mg N = 159
Croatian: 160/80 mg N = 159
English: The recommended AMGEVITA induction dose regimen for adult patients with moderately to severely active Crohn's disease is 80 mg at week 0 followed by 40 mg at week 2.
Croatian: Preporučena indukcijska doza lijeka AMGEVITA u odraslih bolesnika s umjerenom do teškom aktivnom Crohnovom bolešću je 80 mg u nultom tjednu, praćena dozom od 40 mg u drugom tjednu.
English: ● Do not shake the syringe.
Croatian: Ne tresite štrcaljku.
English: Multipack: 6 (3 packs of 2) pre-filled syringes.
Croatian: Višestruko pakiranje: 6 (3 pakiranja od 2) napunjenih štrcaljki.
English: AMGEVITA is used to treat polyarticular juvenile idiopathic arthritis in patients from 2 years and enthesitis-related arthritis in patients from 6 years.
Croatian: AMGEVITA je namijenjena liječenju poliartikularnog juvenilnog idiopatskog artritisa u bolesnika u dobi od 2 godine i starijih i artritisa povezanog s entezitisom u bolesnika u dobi od 6 godina i starijih.
English: It is recommended that you use an antiseptic wash daily on the affected areas.
Croatian: Preporučuje se da zahvaćena područja svakodnevno ispirete antiseptičkom otopinom.
English: The patients received 24 mg/m2 body surface area (BSA) of adalimumab up to a maximum of 20 mg every other week as a single dose via SC injection for at least 24 weeks.
Croatian: Bolesnici su primali 24 mg/m2 tjelesne površine adalimumaba, do maksimalne doze od 20 mg, svaki drugi tjedan kao pojedinačnu dozu s.c. injekcijom kroz najmanje 24 tjedna.
English: The safety and efficacy of adalimumab was assessed in an open-label, multicentre study in 32 children (2 - < 4 years old or aged 4 and above weighing < 15 kg) with moderately to severely active polyarticular JIA.
Croatian: Sigurnost i djelotvornost primjene adalimumaba ocijenjena je u otvorenom, multicentričnom ispitivanju koje je uključivalo 32 djece (u dobi od 2 do manje od 4 godine ili u dobi od 4 godine i više i tjelesne težine manje od 15 kg) s umjerenim do teškim aktivnim poliartikularnim JIA.
English: The pre-filled syringe or pre-filled pen may be stored at temperatures up to a maximum of 25°C for a period of up to 14 days.
Croatian: Napunjena štrcaljka ili napunjena brizgalica može se čuvati na temperaturama do maksimalno 25°C u trajanju do 14 dana.
English: AMGEVITA single use SureClick pre-filled pen For subcutaneous use
Croatian: AMGEVITA SureClick napunjena brizgalica za jednokratnu primjenu
English: Table 25.
Croatian: Tablica 25.
English: All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or psoriasis patients with a history of PUVA treatment should be examined for the presence of nonmelanoma skin cancer prior to and during treatment with AMGEVITA.
Croatian: Sve bolesnike, a posebno one koji u anamnezi imaju dugotrajno korištenje imunosupresivne terapije ili bolesnike s psorijazom i PUVA liječenjem u anamnezi, potrebno je prije i za vrijeme liječenja lijekom AMGEVITA pregledavati u svrhu otkrivanja nemelanomskog karcinoma kože.
English: Starting at Week 4
Croatian: Doza održavanja počevši od 4. tjedna
English: There is an increased background risk for lymphoma and leukaemia in rheumatoid arthritis patients with long-standing highly active, inflammatory disease, which complicates the risk estimation.
Croatian: Procjenu rizika otežava i inače povećani rizik od razvoja limfoma i leukemije u bolesnika s reumatoidnim artritisom s dugotrajnom, izrazito aktivnom upalnom bolešću.
English: Following subcutaneous administration of 40 mg of adalimumab every other week in adult nonradiographic axial spondyloarthritis patients, the mean (±SD) trough steady-state concentration at Week 68 was 8.0 ± 4.6 g/ml.
Croatian: Nakon supkutane primjene adalimumaba od 40 mg svaki drugi tjedan u odraslih bolesnika s ne-radiografskim aksijalnim spondiloarthritisom, srednja vrijednost (± SD) ravnotežne koncentracije u 68. tjednu bila je 8,0 ± 4,6 μg/ml.
English: No malignancies were observed in 77 paediatric patients with an exposure of 80.0 patient-years during an adalimumab trial in paediatric patients with chronic plaque psoriasis.
Croatian: Zloćudne bolesti nisu primijećene ni u 77 pedijatrijskih bolesnika s izloženošću od 80,0 bolesnik-godina u ispitivanju adalimumaba provedenom u pedijatrijskih bolesnika s kroničnom plak psorijazom.
English: ACR 70 6 months 12 months
Croatian: ACR 70 6 mjeseci 12 mjeseci
English: Your doctor may also prescribe an initial dose of 40 mg which may be administered one week prior to the start of the usual dose.
Croatian: Djetetov liječnik može propisati i početnu dozu od 40 mg, koja se može primijeniti tjedan dana prije početka primjene uobičajene doze.
English: The combination of AMGEVITA and anakinra is not recommended (see section 4.4 “Concurrent administration of biologic DMARDS or TNF-antagonists”).
Croatian: Kombinirana terapija lijekom AMGEVITA i anakinrom se ne preporučuje (vidjeti dio 4.4 “Istodobna primjena bioloških antireumatika koji modificiraju tijek bolesti ili antagonista TNF-a“).
English: If you do not respond well enough to these medicines, you will be given AMGEVITA to treat your polyarticular juvenile idiopathic arthritis or enthesitis-related arthritis.
Croatian: Ako na njih ne reagirate dovoljno dobro, u svrhu liječenja poliartikularnog juvenilnog idiopatskog artritisa ili artritisa povezanog s entezitisom bit će Vam propisan lijek AMGEVITA.
English: The pre-filled syringe must be protected from light, and discarded if not used within the 14-day period.
Croatian: Napunjenu brizgalicu morate zaštititi od svjetlosti i morate je baciti ako nije iskorištena u roku od 14 dana.
English: The usual dose for adults with rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of ankylosing spondylitis, and for patients with psoriatic arthritis is 40 mg given every other week as a single dose.
Croatian: Uobičajena doza u odraslih osoba oboljelih od reumatoidnog artritisa, ankilozantnog spondilitisa, aksijalnog spondiloartritisa bez radiološkog dokaza AS-a te u bolesnika sa psorijatičnim artritisom iznosi 40 mg, a primjenjuje se kao pojedinačna doza svaki drugi tjedan.
English: Patients should be tested for HBV infection before initiating treatment with AMGEVITA.
Croatian: Bolesnike je potrebno prije početka terapije lijekom AMGEVITA testirati na HBV infekciju.
English: Your doctor may also prescribe an initial dose of 80 mg which may be administered one week prior to the start of the usual dose.
Croatian: Djetetov liječnik može propisati i početnu dozu od 80 mg, koja se može primijeniti tjedan dana prije početka primjene uobičajene doze.
English: AMGEVITA is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.
Croatian: AMGEVITA je indicirana za liječenje teške kronične plak psorijaze u djece i adolescenata u dobi od 4 ili više godina u kojih nije postignut zadovoljavajući odgovor ili koji nisu prikladni kandidati za topikalnu terapiju i fototerapije.
English: Proportion of patientsa achieving HiSCRb at weeks 24 and 36 after treatment reassignment from weekly adalimumab at week 12
Croatian: Tablica 22. Udio bolesnikaa koji su postigli HiSCRb u 24. i 36. tjednu po preraspodjeli, nakon što su 12 tjedana primali adalimumab svaki tjedan
English: 4 pre-filled syringes.
Croatian: 4 napunjene štrcaljke.
English: AMGEVITA should be used with caution in patients with mild heart failure (NYHA class I/II).
Croatian: Zato se bolesnicima s blagim zatajenjem srca (NYHA razred I/II) AMGEVITA mora davati oprezno.
English: 40 mg adalimumab every other week
Croatian: 40 mg adalimumaba svaki drugi tjedan
English: All subjects received open-label induction therapy at a dose based on their baseline body weight: 160 mg at week 0 and 80 mg at week 2 for subjects ≥ 40 kg, and 80 mg and 40 mg, respectively, for subjects < 40 kg.
Croatian: Svi ispitanici su primali otvorenu indukcijsku terapiju u dozi određenoj prema njihovoj početnoj tjelesnoj težini: 160 mg u nultom tjednu i 80 mg u drugom tjednu za ispitanike tjelesne težine ≥ 40 kg, odnosno 80 mg i 40 mg za ispitanike tjelesne težine < 40 kg.
English: The pre-filled syringe or pre-filled pen must be protected from light, and discarded if not used within the 14-day period.
Croatian: Napunjenu štrcaljku ili napunjenu brizgalicu se mora zaštiti od svjetlosti i zbrinuti ako se ne iskoristi unutar 14 dana.
English: Adults with plaque psoriasis
Croatian: Odrasli s plak psorijazom
English: Adalimumab was assessed in a multicentre, randomised, double-blind clinical trial designed to evaluate the efficacy and safety of induction and maintenance treatment with doses dependent on body weight (< 40 kg or ≥ 40 kg) in 192 paediatric subjects between the ages of 6 and 17 (inclusive) years, with moderate to severe Crohn´s disease (CD) defined as Paediatric Crohn's Disease Activity Index (PCDAI) score > 30.
Croatian: Djelotvornost i sigurnost adalimumaba ispitivane su u multicentričnom, randomiziranom, dvostruko slijepom kliničkom ispitivanju indukcijske terapije i terapije održavanja dozama ovisnim o tjelesnoj težini (< 40 kg ili ≥ 40 kg) u 192 pedijatrijska ispitanika u dobi između (i uključujući) 6 i 17 godina s umjerenom do teškom Crohnovom bolešću (engl.
English: F. Stretch or pinch your injection site to create a firm surface.
Croatian: Rastegnite kožu ili uhvatite nabor kože na mjestu injiciranja kako biste stvorili čvrstu površinu.